Universität zu Köln

Hoenigl, Martin ORCID: 0000-0002-1653-2824, Sprute, Rosanne ORCID: 0000-0003-2457-6437, Arastehfar, Amir, Perfect, John R., Lass-Floerl, Cornelia, Bellmann, Romuald, Prattes, Juergen ORCID: 0000-0001-5751-9311, Thompson, George R., III, Wiederhold, Nathan P., Al Obaidi, Mohanad M., Willinger, Birgit, Arendrup, Maiken C., Koehler, Philipp, Oliverio, Matteo ORCID: 0000-0002-7969-2796, Egger, Matthias, Schwartz, Ilan S., Cornely, Oliver A. ORCID: 0000-0001-9599-3137, Pappas, Peter G. and Krause, Robert (2022). Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opin. Investig. Drugs, 31 (8). S. 795 - 813. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1744-7658

Full text not available from this repository.

Abstract

Introduction The epidemiology of invasive Candida infections is evolving. Infections caused by non-albicans Candida spp. are increasing; however, the antifungal pipeline is more promising than ever and is enriched with repurposed drugs and agents that have new mechanisms of action. Despite progress, unmet needs in the treatment of invasive candidiasis remain, and there are still too few antifungals that can be administered orally or that have CNS penetration. Areas covered The authors shed light on those antifungal agents active against Candida that are in early- and late-stage clinical development. Mechanisms of action and key pharmacokinetic and pharmacodynamic properties are discussed. Insights are offered on the potential future roles of the investigational agents MAT-2203, oteseconazole, ATI-2307, VL-2397, NP-339, and the repurposed drug miltefosine. Expert opinion Ibrexafungerp and fosmanogepix have novel mechanisms of action and will provide effective options for the treatment of Candida infections (including those caused by multiresistant Candida spp). Rezafungin, an echinocandin with an extended half-life allowing for once weekly administration, will be particularly valuable for outpatient treatment and prophylaxis. Despite this, there is an urgent need to garner clinical data on investigational drugs, especially in the current rise of azole-resistant and multidrug-resistant Candida spp.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Hoenigl, Martin UNSPECIFIED orcid.org/0000-0002-1653-2824 UNSPECIFIED Sprute, Rosanne UNSPECIFIED orcid.org/0000-0003-2457-6437 UNSPECIFIED Arastehfar, Amir UNSPECIFIED UNSPECIFIED UNSPECIFIED Perfect, John R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lass-Floerl, Cornelia UNSPECIFIED UNSPECIFIED UNSPECIFIED Bellmann, Romuald UNSPECIFIED UNSPECIFIED UNSPECIFIED Prattes, Juergen UNSPECIFIED orcid.org/0000-0001-5751-9311 UNSPECIFIED Thompson, George R., III UNSPECIFIED UNSPECIFIED UNSPECIFIED Wiederhold, Nathan P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Al Obaidi, Mohanad M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Willinger, Birgit UNSPECIFIED UNSPECIFIED UNSPECIFIED Arendrup, Maiken C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Koehler, Philipp UNSPECIFIED UNSPECIFIED UNSPECIFIED Oliverio, Matteo UNSPECIFIED orcid.org/0000-0002-7969-2796 UNSPECIFIED Egger, Matthias UNSPECIFIED UNSPECIFIED UNSPECIFIED Schwartz, Ilan S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Cornely, Oliver A. UNSPECIFIED orcid.org/0000-0001-9599-3137 UNSPECIFIED Pappas, Peter G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Krause, Robert UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-695725
DOI:	10.1080/13543784.2022.2086120
Journal or Publication Title:	Expert Opin. Investig. Drugs
Volume:	31
Number:	8
Page Range:	S. 795 - 813
Date:	2022
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1744-7658
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language BROAD-SPECTRUM ANTIFUNGAL; IN-VITRO ACTIVITY; AMPHOTERICIN-B; MOUSE MODEL; ECHINOCANDIN; T-2307; EFFICACY; ALBICANS; MILTEFOSINE; ARYLAMIDINE Multiple languages Pharmacology & Pharmacy Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/69572